Prevention of neuropathology in the mouse model of Hurler syndrome

Annals of Neurology
Nathalie DesmarisJ M Heard

Abstract

A defect of the lysosomal enzyme alpha-L-iduronidase (IDUA) interrupts heparan and dermatan sulfate degradation and causes neuropathology in children with severe forms of mucopolysaccharidosis type I (MPSI, Hurler syndrome). Enzyme substitution therapy is beneficial but ineffective on the central nervous system. We could deliver the missing enzyme to virtually the entire brain of MPSI mice through a single injection of gene transfer vectors derived from adenoassociated virus serotype 2 (AAV2) or 5 (AAV5) coding for human IDUA. This result was reproducibly achieved with both vector types in 46 mice and persisted for at least 26 weeks. Success was more frequent, enzyme activity was higher, and corrected areas were broader with AAV5 than with AAV2 vectors. Treatment presumably reversed and certainly prevented the accumulation of GM2 and GM3 gangliosides, which presumably participates to neuropathology. Lysosomal distension, which already was present at the time of treatment, had disappeared from both brain hemispheres and was minimal in the cerebellum in mice analyzed 26 weeks after injection. This study shows that pathology associated with MPSI can be prevented in the entire mouse brain by a single AAV vector injection, providing...Continue Reading

References

Jul 1, 1991·Journal of the Neurological Sciences·S U WalkleyJ Y Wu
Jan 1, 1988·Acta Neuropathologica·S U WalkleyR M Shull
Apr 1, 1989·The Journal of Clinical Investigation·E H BirkenmeierC J Wawrzyniak
Dec 20, 1994·Proceedings of the National Academy of Sciences of the United States of America·R M ShullE F Neufeld
Jun 1, 1994·Protein Expression and Purification·E D KakkisE F Neufeld
Apr 29, 1998·Human Gene Therapy·A SalvettiP Moullier
Jul 11, 1998·Clinical Genetics·C RussellL A Clarke
Jan 9, 1999·Journal of Virology·J A ChioriniR M Kotin
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·A BoschJ M Heard
Feb 15, 2001·The New England Journal of Medicine·E D KakkisE F Neufeld
Jan 12, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haiyan FuJoseph Muenzer
Apr 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·Andrew I BrooksBeverly L Davidson
Nov 20, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nicole BrumentAnna Salvetti
Feb 11, 2003·Proceedings of the National Academy of Sciences of the United States of America·Kazuhiro OhmiElizabeth F Neufeld
Sep 13, 2003·International Review of Neurobiology·Assumpció Bosch, Jean Michel Heard

❮ Previous
Next ❯

Citations

Jan 26, 2006·Journal of Inherited Metabolic Disease·M CamassolaN B Nardi
Jun 10, 2006·Journal of Inherited Metabolic Disease·Alain FischerMarina Cavazzana-Calvo
Mar 10, 2007·Journal of Inherited Metabolic Disease·C SevinN Cartier
Apr 11, 2008·Gene Therapy·I E AlexanderJ Christodoulou
Jul 1, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Cyrille VaillendElise Peltekian
Dec 9, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·N Matthew EllinwoodMarie-Anne Colle
Mar 10, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haiyan FuDouglas M McCarty
Dec 21, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Dolan SondhiRonald G Crystal
Oct 13, 2005·Human Gene Therapy·Alessandra Biffi, Luigi Naldini
Jul 8, 2005·Human Gene Therapy·Corinna BurgerRonald J Mandel
Mar 18, 2008·Neurosurgical Focus·Gregory M Enns, Stephen L Huhn
May 23, 2007·Proceedings of the National Academy of Sciences of the United States of America·Marco A PassiniSeng H Cheng
Jan 22, 2011·Neurochemical Research·Karie A HeineckeThomas N Seyfried
Sep 12, 2006·Annual Review of Pharmacology and Toxicology·A G de Boer, P J Gaillard
Aug 21, 2007·Expert Opinion on Biological Therapy·Alessandra Biffi, Luigi Naldini
Dec 17, 2014·Expert Opinion on Drug Delivery·Daniel A WolfWalter C Low
May 10, 2011·Expert Opinion on Biological Therapy·Angela Gritti
Aug 31, 2007·Expert Opinion on Biological Therapy·Katherine P Ponder, Mark E Haskins
May 19, 2009·American Journal of Medical Genetics. Part a·Carmela Di DomenicoPaola Di Natale
Jun 5, 2012·Molecular Genetics and Metabolism·Lorne A ClarkeHernan Amartino
Dec 30, 2008·Biochimica Et Biophysica Acta·Steven U Walkley, Marie T Vanier
Jun 9, 2016·Human Gene Therapy·Michaël HocquemillerNathalie Cartier
Aug 25, 2016·Molecular Genetics and Metabolism Reports·Li OuChester B Whitley
Mar 21, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark S Sands, Beverly L Davidson
May 24, 2006·Annals of Neurology·Carine CironJean-Michel Heard
Mar 14, 2007·Current Opinion in Neurology·Monica Cardone
Aug 8, 2007·Biotechnology and Bioengineering·Ruben J BoadoWilliam M Pardridge
May 28, 2020·Cold Spring Harbor Protocols·Miguel Sena-Esteves, Guangping Gao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.